Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties

P. Uma Devi, F. E. Solomon, A. C. Sharada

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The tumor inhibitory and radiomodifying effects of plumbagin (Pl), a naphthoquinone isolated from Plumbago rosea, on mouse Ehrlich ascites carcinoma was studied. Tumor response was assessed by increase in life span (% ILS) and animal survival at 120 days. The acute LD50 of plumbagin in normal mice was 9.4 mg/kg body weight. Single doses from 2 to 6 mg/kg Pl, given intraperitoneally (i.p.), produced inhibition of exponentially growing tumors. However, increases in dose above 3 mg/kg did not increase 120 day survival significantly over that produced by 3 mg/kg. Multiple dose treatment, starting from 24 h after tumor cell inoculation, showed that a total dose of 9 mg/kg, administered in three fractions of 3 mg/kg, once daily, gave the maximum %ILS and tumor free survival. Combination of radiation (RT, 7.5 Gy to the abdomen) after the first Pl dose (1-3 mg/kg/fraction) synergistically increased mouse survival at 120 days. The tumor inhibitory effect was less pronounced when treatment was started at more advanced tumor stages, but combination of low dose fractions (2.5 or 3 mg/kg/fraction) with RT enhanced the %ILS and animal survival. Higher dose fractions in combination with radiation were not tolerated by the mice. DNA appears to be the likely target of Pl cytotoxicity; the mechanism of interaction of Pl + RT in enhancing tumor response is not clear.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalPharmaceutical Biology
Volume37
Issue number3
DOIs
Publication statusPublished - 06-11-1999
Externally publishedYes

Fingerprint

Naphthoquinones
Neoplasms
Plumbaginaceae
Radiation
plumbagin
Lethal Dose 50
Ascites
Abdomen
Body Weight
Carcinoma
DNA

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine

Cite this

Uma Devi, P. ; Solomon, F. E. ; Sharada, A. C. / Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties. In: Pharmaceutical Biology. 1999 ; Vol. 37, No. 3. pp. 231-236.
@article{c0705a8afa11492e917f272da210f480,
title = "Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties",
abstract = "The tumor inhibitory and radiomodifying effects of plumbagin (Pl), a naphthoquinone isolated from Plumbago rosea, on mouse Ehrlich ascites carcinoma was studied. Tumor response was assessed by increase in life span ({\%} ILS) and animal survival at 120 days. The acute LD50 of plumbagin in normal mice was 9.4 mg/kg body weight. Single doses from 2 to 6 mg/kg Pl, given intraperitoneally (i.p.), produced inhibition of exponentially growing tumors. However, increases in dose above 3 mg/kg did not increase 120 day survival significantly over that produced by 3 mg/kg. Multiple dose treatment, starting from 24 h after tumor cell inoculation, showed that a total dose of 9 mg/kg, administered in three fractions of 3 mg/kg, once daily, gave the maximum {\%}ILS and tumor free survival. Combination of radiation (RT, 7.5 Gy to the abdomen) after the first Pl dose (1-3 mg/kg/fraction) synergistically increased mouse survival at 120 days. The tumor inhibitory effect was less pronounced when treatment was started at more advanced tumor stages, but combination of low dose fractions (2.5 or 3 mg/kg/fraction) with RT enhanced the {\%}ILS and animal survival. Higher dose fractions in combination with radiation were not tolerated by the mice. DNA appears to be the likely target of Pl cytotoxicity; the mechanism of interaction of Pl + RT in enhancing tumor response is not clear.",
author = "{Uma Devi}, P. and Solomon, {F. E.} and Sharada, {A. C.}",
year = "1999",
month = "11",
day = "6",
doi = "10.1076/phbi.37.3.231.6299",
language = "English",
volume = "37",
pages = "231--236",
journal = "Pharmaceutical Biology",
issn = "1388-0209",
publisher = "Informa Healthcare",
number = "3",

}

Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties. / Uma Devi, P.; Solomon, F. E.; Sharada, A. C.

In: Pharmaceutical Biology, Vol. 37, No. 3, 06.11.1999, p. 231-236.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties

AU - Uma Devi, P.

AU - Solomon, F. E.

AU - Sharada, A. C.

PY - 1999/11/6

Y1 - 1999/11/6

N2 - The tumor inhibitory and radiomodifying effects of plumbagin (Pl), a naphthoquinone isolated from Plumbago rosea, on mouse Ehrlich ascites carcinoma was studied. Tumor response was assessed by increase in life span (% ILS) and animal survival at 120 days. The acute LD50 of plumbagin in normal mice was 9.4 mg/kg body weight. Single doses from 2 to 6 mg/kg Pl, given intraperitoneally (i.p.), produced inhibition of exponentially growing tumors. However, increases in dose above 3 mg/kg did not increase 120 day survival significantly over that produced by 3 mg/kg. Multiple dose treatment, starting from 24 h after tumor cell inoculation, showed that a total dose of 9 mg/kg, administered in three fractions of 3 mg/kg, once daily, gave the maximum %ILS and tumor free survival. Combination of radiation (RT, 7.5 Gy to the abdomen) after the first Pl dose (1-3 mg/kg/fraction) synergistically increased mouse survival at 120 days. The tumor inhibitory effect was less pronounced when treatment was started at more advanced tumor stages, but combination of low dose fractions (2.5 or 3 mg/kg/fraction) with RT enhanced the %ILS and animal survival. Higher dose fractions in combination with radiation were not tolerated by the mice. DNA appears to be the likely target of Pl cytotoxicity; the mechanism of interaction of Pl + RT in enhancing tumor response is not clear.

AB - The tumor inhibitory and radiomodifying effects of plumbagin (Pl), a naphthoquinone isolated from Plumbago rosea, on mouse Ehrlich ascites carcinoma was studied. Tumor response was assessed by increase in life span (% ILS) and animal survival at 120 days. The acute LD50 of plumbagin in normal mice was 9.4 mg/kg body weight. Single doses from 2 to 6 mg/kg Pl, given intraperitoneally (i.p.), produced inhibition of exponentially growing tumors. However, increases in dose above 3 mg/kg did not increase 120 day survival significantly over that produced by 3 mg/kg. Multiple dose treatment, starting from 24 h after tumor cell inoculation, showed that a total dose of 9 mg/kg, administered in three fractions of 3 mg/kg, once daily, gave the maximum %ILS and tumor free survival. Combination of radiation (RT, 7.5 Gy to the abdomen) after the first Pl dose (1-3 mg/kg/fraction) synergistically increased mouse survival at 120 days. The tumor inhibitory effect was less pronounced when treatment was started at more advanced tumor stages, but combination of low dose fractions (2.5 or 3 mg/kg/fraction) with RT enhanced the %ILS and animal survival. Higher dose fractions in combination with radiation were not tolerated by the mice. DNA appears to be the likely target of Pl cytotoxicity; the mechanism of interaction of Pl + RT in enhancing tumor response is not clear.

UR - http://www.scopus.com/inward/record.url?scp=0032708540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032708540&partnerID=8YFLogxK

U2 - 10.1076/phbi.37.3.231.6299

DO - 10.1076/phbi.37.3.231.6299

M3 - Article

AN - SCOPUS:0032708540

VL - 37

SP - 231

EP - 236

JO - Pharmaceutical Biology

JF - Pharmaceutical Biology

SN - 1388-0209

IS - 3

ER -